Drug Interactions With New Synthetic Opioids
暂无分享,去创建一个
M. Farré | M. Torrens | F. Fonseca | C. Pérez-Mañá | E. Papaseit | A. Farré
[1] M. Barratt,et al. Global Drug Survey , 2020 .
[2] Stewart E. Glaspole. Stockley’s Drug Interactions , 2018 .
[3] R. Giorgetti,et al. Pharmacotoxicology of Non-fentanyl Derived New Synthetic Opioids , 2018, Front. Pharmacol..
[4] S. Schnoll. Misconceptions and Realities of the Prescription Opioid Epidemic , 2018, Clinical pharmacology and therapeutics.
[5] Blair H. Smith,et al. Incidence of iatrogenic opioid dependence or abuse in patients with pain who were exposed to opioid analgesic therapy: a systematic review and meta‐analysis , 2018, British journal of anaesthesia.
[6] Lawrence Scholl,et al. Overdose deaths involving opioids, cocaine, and psychostimulants — United States, 2015–2016 , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[7] B. Piper,et al. Trends in Medical Use of Opioids in the U.S., 2006-2016. , 2018, American journal of preventive medicine.
[8] S. Vosburg,et al. Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies , 2018, The American journal on addictions.
[9] N. Volkow,et al. Medication development in opioid addiction: Meaningful clinical end points , 2018, Science Translational Medicine.
[10] Y. Shaham,et al. Fentanyl-Induced Brain Hypoxia Triggers Brain Hyperglycemia and Biphasic Changes in Brain Temperature , 2018, Neuropsychopharmacology.
[11] M. Liechti,et al. Opioid‐induced inhibition of the human 5‐HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome , 2018, British journal of pharmacology.
[12] N. Volkow. Medications for opioid use disorder: bridging the gap in care , 2017, The Lancet.
[13] R. Pacifici,et al. Acute Intoxications and Fatalities From Illicit Fentanyl and Analogues: An Update , 2017, Therapeutic drug monitoring.
[14] J. Rehm,et al. The 'fentanyl epidemic' in Canada - Some cautionary observations focusing on opioid-related mortality. , 2017, Preventive medicine.
[15] Ya-Han Lee,et al. Current Impact and Application of Abuse-Deterrent Opioid Formulations in Clinical Practice. , 2017, Pain physician.
[16] R. Pacifici,et al. European Drug Users at Risk from Illicit Fentanyls Mix , 2017, Front. Pharmacol..
[17] Jill Barr-Walker,et al. Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review , 2017, Neuropharmacology.
[18] W. Hall,et al. Trends in heroin and pharmaceutical opioid overdose deaths in Australia. , 2017, Drug and alcohol dependence.
[19] T. Kerr,et al. Chronic pain and opioid misuse: a review of reviews , 2017, Substance Abuse Treatment, Prevention, and Policy.
[20] G. Pasternak,et al. Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace , 2017, Neuropharmacology.
[21] F. Carvalho,et al. Opioids in the Frame of New Psychoactive Substances Network: A Complex Pharmacological and Toxicological Issue. , 2017, Current molecular pharmacology.
[22] T. Kraemer,et al. Studies on the metabolism of the fentanyl-derived designer drug butyrfentanyl in human in vitro liver preparations and authentic human samples using liquid chromatography-high resolution mass spectrometry (LC-HRMS). , 2017, Drug testing and analysis.
[23] J. Zawilska. An Expanding World of Novel Psychoactive Substances: Opioids , 2017, Front. Psychiatry.
[24] P. Mansky,et al. Misuse of Novel Synthetic Opioids: A Deadly New Trend , 2017, Journal of addiction medicine.
[25] D. Fiellin,et al. Abuse-Deterrent Opioid Formulations - Putting the Potential Benefits into Perspective. , 2017, The New England journal of medicine.
[26] N. Volkow,et al. The Role of Science in Addressing the Opioid Crisis. , 2017, The New England journal of medicine.
[27] Quan Zhou,et al. Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management , 2017, Journal of pain research.
[28] H. Gréen,et al. In Vitro and In Vivo Metabolite Identification Studies for the New Synthetic Opioids Acetylfentanyl, Acrylfentanyl, Furanylfentanyl, and 4-Fluoro-Isobutyrylfentanyl , 2017, The AAPS Journal.
[29] B. Martin,et al. Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use — United States, 2006–2015 , 2017, MMWR. Morbidity and mortality weekly report.
[30] Kunihiko Takahashi,et al. Epidemiology of overdose episodes from the period prior to hospitalization for drug poisoning until discharge in Japan: An exploratory descriptive study using a nationwide claims database , 2017, Journal of epidemiology.
[31] J. Suzuki,et al. A review: Fentanyl and non-pharmaceutical fentanyls. , 2017, Drug and alcohol dependence.
[32] D. Tracy,et al. Novel psychoactive substances: types, mechanisms of action, and effects , 2017, British Medical Journal.
[33] G. Janis,et al. A case of U-47700 overdose with laboratory confirmation and metabolite identification , 2017, Clinical toxicology.
[34] U. Garg,et al. Analysis of U-47700, a Novel Synthetic Opioid, in Human Urine by LC-MS-MS and LC-QToF. , 2016, Journal of analytical toxicology.
[35] Iain M McIntyre,et al. A Fatality Related to the Synthetic Opioid U-47700: Postmortem Concentration Distribution. , 2016, Journal of analytical toxicology.
[36] Y. Ohtsu,et al. A fatal poisoning case by intravenous injection of "bath salts" containing acetyl fentanyl and 4-methoxy PV8. , 2016, Forensic science international.
[37] B. Goldberger,et al. Illicit Fentanyl-Related Fatalities in Florida: Toxicological Findings. , 2016, Journal of analytical toxicology.
[38] M. Huestis,et al. Metabolism of Carfentanil, an Ultra-Potent Opioid, in Human Liver Microsomes and Human Hepatocytes by High-Resolution Mass Spectrometry , 2016, The AAPS Journal.
[39] Mingshe Zhu,et al. Metabolic characterization of AH-7921, a synthetic opioid designer drug: in vitro metabolic stability assessment and metabolite identification, evaluation of in silico prediction, and in vivo confirmation. , 2016, Drug testing and analysis.
[40] I. Takase,et al. An autopsy case of acetyl fentanyl intoxication caused by insufflation of 'designer drugs'. , 2016, Legal medicine.
[41] A. Kjellgren,et al. The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations. , 2016, The International journal on drug policy.
[42] I. Maremmani,et al. Treatment Approaches for Patients With Opioid Use Disorder and Chronic Noncancer Pain: a Literature Review , 2016 .
[43] R. Chou,et al. CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. , 2016, JAMA.
[44] J. Karalliedde,et al. Adverse Drug Interactions : A Handbook for Prescribers, Second Edition , 2016 .
[45] R. Chou,et al. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. , 2016, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[46] P. Griffiths,et al. Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe. , 2015, The International journal on drug policy.
[47] Janet Brink. The Misuse of Prescription Opioids: A Threat for Europe? , 2015 .
[48] R. Chou,et al. The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop , 2015, Annals of Internal Medicine.
[49] J. Mørland,et al. Pharmacokinetic interactions between ethanol and heroin: a study on post-mortem cases. , 2014, Forensic science international.
[50] R. Altman,et al. PharmGKB summary: tramadol pathway. , 2014, Pharmacogenetics and genomics.
[51] E. Sellers,et al. Preventing and managing aberrant drug-related behavior in primary care: systematic review of outcomes evidence. , 2014, Journal of opioid management.
[52] Laura D. Knight,et al. Quantitative measurement of acetyl fentanyl and acetyl norfentanyl in human urine by LC-MS/MS. , 2014, Analytical chemistry.
[53] M. Farré,et al. Reacciones adversas de medicamentos relacionadas con el abuso y formas farmacéuticas disuasorias , 2013 .
[54] J. Mørland,et al. Levels of heroin and its metabolites in blood and brain extracellular fluid after i.v. heroin administration to freely moving rats , 2013, British journal of pharmacology.
[55] J. Gudin. Opioid therapies and cytochrome p450 interactions. , 2012, Journal of pain and symptom management.
[56] R. de la Torre,et al. MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant? , 2012, Front. Gene..
[57] Edward W Boyer,et al. Management of opioid analgesic overdose. , 2012, The New England journal of medicine.
[58] Wesley T. Lindsey,et al. Drug Interactions between Common Illicit Drugs and Prescription Therapies , 2012, The American journal of drug and alcohol abuse.
[59] D. Foster,et al. Opioid pharmacokinetic drug-drug interactions. , 2011, The American journal of managed care.
[60] Monique L. Smith,et al. Powerful behavioral interactions between methamphetamine and morphine , 2011, Pharmacology Biochemistry and Behavior.
[61] E. Kharasch,et al. Sensitivity of Intravenous and Oral Alfentanil and Pupillary Miosis as Minimal and Noninvasive Probes for Hepatic and First‐Pass CYP3A Induction , 2011, Clinical pharmacology and therapeutics.
[62] D. Rybin,et al. Identifying prescription opioid use disorder in primary care: Diagnostic characteristics of the Current Opioid Misuse Measure (COMM) , 2011, PAIN®.
[63] R. Ferner. Adverse Drug Interactions: A Handbook for Prescribers , 2011 .
[64] S. Butler,et al. Cross Validation of the Current Opioid Misuse Measure to Monitor Chronic Pain Patients on Opioid Therapy , 2010, The Clinical journal of pain.
[65] R. Tyndale,et al. Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment. , 2010, Annual review of pharmacology and toxicology.
[66] G. Tucker,et al. The Consequences of 3,4-Methylenedioxymethamphetamine Induced CYP2D6 Inhibition in Humans , 2008, Journal of clinical psychopharmacology.
[67] S. Butler,et al. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). , 2008, The journal of pain : official journal of the American Pain Society.
[68] Timothy A. Erickson,et al. Fentanyl epidemic in Chicago, Illinois and surrounding Cook County , 2008, Clinical toxicology.
[69] Gretchen M. Brophy. Stockleyʼs Drug Interactions Pocket Companion , 2007 .
[70] George S Behonick,et al. Fatalities Associated with Fentanyl and Co‐administered Cocaine or Opiates , 2007, Journal of forensic sciences.
[71] P. Shekelle,et al. The addiction behaviors checklist: validation of a new clinician-based measure of inappropriate opioid use in chronic pain. , 2006, Journal of pain and symptom management.
[72] L. Webster,et al. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. , 2005, Pain medicine.
[73] A. Polettini,et al. The role of cocaine in heroin-related deaths. Hypothesis on the interaction between heroin and cocaine. , 2005, Forensic science international.
[74] E. Kharasch,et al. METABOLISM OF ALFENTANIL BY CYTOCHROME P4503A (CYP3A) ENZYMES , 2005, Drug Metabolism and Disposition.
[75] Ruth E. Winecker,et al. Fatal intravenous fentanyl abuse: four cases involving extraction of fentanyl from transdermal patches. , 2004, The American journal of forensic medicine and pathology.
[76] A. J. Clark,et al. Cannabis reduces opioid dose in the treatment of chronic non-cancer pain. , 2003, Journal of pain and symptom management.
[77] R. Wise,et al. Intravenous self‐administration of methamphetamine‐heroin (speedball) combinations under a progressive‐ratio schedule of reinforcement in rats , 2000, Neuroreport.
[78] A. Polettini,et al. The role of alcohol abuse in the etiology of heroin-related deaths. Evidence for pharmacokinetic interactions between heroin and alcohol. , 1999, Journal of analytical toxicology.
[79] K. Robertson. The European Monitoring Centre for Drugs and Drug Addiction , 1998 .
[80] P. Beaune,et al. Possible involvement of multiple cytochrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil. , 1997, Biochemical pharmacology.
[81] H. Van Aken,et al. Remifentanil: A Novel, Short-Acting, mu-Opioid , 1996, Anesthesia and analgesia.
[82] R. Foltin,et al. The cardiovascular and subjective effects of intravenous cocaine and morphine combinations in humans. , 1992, The Journal of pharmacology and experimental therapeutics.
[83] K. Foley,et al. Cocaine and morphine interaction in acute and chronic cancer pain , 1987, PAIN®.
[84] K. Preston,et al. Evaluation of mixtures of morphine and d-amphetamine for subjective and physiological effects. , 1986, Drug and alcohol dependence.
[85] P. Schoeffler,et al. Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. , 1982, British journal of anaesthesia.
[86] H. Fields,et al. Naloxone dose dependently produces analgesia and hyperalgesia in postoperative pain , 1979, Nature.
[87] Unite Evaluations. UNITED NATIONS OFFICE ON DRUGS AND CRIME-INDEPENDENT EVALUATION SECTION , 2020 .
[88] G. Pasternak,et al. Novel Synthetic Opioids and Overdose Deaths: Tip of the Iceberg? , 2018, Neuropsychopharmacology.
[89] Rachael Rzasa Lynn,et al. Naloxone dosage for opioid reversal: current evidence and clinical implications , 2018, Therapeutic advances in drug safety.
[90] J. V. van Amsterdam,et al. The Misuse of Prescription Opioids: A Threat for Europe? , 2015, Current drug abuse reviews.
[91] T. Atkinson. Interactions between Pain Medications and Illicit Street Drugs , 2014 .
[92] M. Farré,et al. [Abuse-related adverse drug reactions and abuse deterrent formulations]. , 2013, Medicina clinica.
[93] S. Jortani,et al. Handbook of Drug Interactions , 2012, Humana Press.
[94] K. Bettinardi-Angres,et al. NON-MEDICAL USE OF PRESCRIPTION DRUGS , 2012 .
[95] A. Jatoi,et al. A systematic compilation of reports published on opioid-related problems. , 2011, Journal of opioid management.
[96] M. Meyer,et al. Qualitative studies on the metabolism and the toxicological detection of the fentanyl-derived designer drugs 3-methylfentanyl and isofentanyl in rats using liquid chromatography–linear ion trap–mass spectrometry (LC-MSn) , 2011, Analytical and Bioanalytical Chemistry.
[97] Howard S. Smith,et al. Opioid metabolism. , 2009, Mayo Clinic proceedings.
[98] Jos H Beijnen,et al. Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. , 2006, Current clinical pharmacology.
[99] S. Ferrara,et al. Fatality due to fentanyl-cocaine intoxication resulting in a fall , 2005, International Journal of Legal Medicine.
[100] E. Kharasch,et al. Metabolism of alfentanil by cytochrome P 4503 A ( CYP 3 A ) enzymes , 2004 .
[101] L. Raymon,et al. Handbook of Drug Interactions , 2004, Forensic Science and Medicine.
[102] S. Hemby,et al. Synergistic elevations in nucleus accumbens extracellular dopamine concentrations during self-administration of cocaine/heroin combinations (Speedball) in rats. , 1999, The Journal of pharmacology and experimental therapeutics.
[103] J. Boscarino,et al. Substance Abuse and Rehabilitation Dovepress Opioid-use Disorder among Patients on Long-term Opioid Therapy: Impact of Final Dsm-5 Diagnostic Criteria on Prevalence and Correlates , 2022 .